INVENIO THERAPEUTICS, INC.

Basic Information

1100 CEDAR AVE, STE 285
CLEVELAND, OH, 44106-3007

Company Profile

n/a

Additional Details

Field Value
DUNS: 801479333
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Original Phase 1 Title: Identifying Small Molecule Inhibitors of HdmX using Cell-based Screening Revised Title: Development of a Novel HdmX Inhibitor for Leukemia

    Amount: $775,796.00

    DESCRIPTION provided by applicant Despite advances in cancer therapy the majority of cancer therapeutics in use still exhibit significant toxicity and induce DNA damage The DNA damage though tox ...

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  2. Natural product-derived differentiation agents for AML

    Amount: $853,202.00

    DESCRIPTION (provided by applicant): Though AML is one of the most common forms of leukemia in adults; the 5 year survival is less than 20-50% in adults and significantly lowers in the elderly. The re ...

    SBIR Phase II 2011 Department of Health and Human Services
  3. Plant-derived differentiation agents for AML

    Amount: $142,460.00

    DESCRIPTION (provided by applicant): Plant-derived compounds, particularly alkaloids, have historically been a successful source of currently used therapeutics. Recently, a plant-derived alkaloid was ...

    SBIR Phase I 2008 Department of Health and Human Services
  4. Novel differentiation therapy for AML

    Amount: $128,230.00

    DESCRIPTION (provided by applicant): Acute myeloid leukemia (AML) is one of the most common forms of leukemia in adults and despite advances in treatment the 5 year survival is less than 20-50% in adu ...

    SBIR Phase I 2008 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government